EGFR and non-small cell lung carcinoma: Although different PCR-based approaches have been approved for the analysis of EGFR mutations in liquid biopsies for many years, only recently, NGS panels were recognized by the FDA (Food and Drug Administration) for this purpose in NSCLC patients.